drugset / Trial / NCT00408369

Prophylactic Antimalarial Activity of DB289 in Volunteers

NCT00408369

Phase 1/2 Completed 19 enrolled Immtech Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindPrevention

Summary

To evaluate the prophylactic activity of orally administered DB289 against Plasmodium falciparum in non-immune healthy volunteers who are challenged by the bite of five P. falciparum-infected Anopheles stephensi mosquitoes

Timeline

Start
2006-11
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pafuramidine Small molecule Oral

Indications

No indication recorded.